Patents Examined by Jeff Kushan
-
Patent number: 5179018Abstract: Mammalian monoclonal anti-lipopolysaccharide (LPS) antibodies which react with gram-negative bacteria across different genera are disclosed. The anti-LPS antibodies are useful for the treatment or prevention of gram-negative bacteremia and for the detection of gram-negative microorganisms.Type: GrantFiled: October 14, 1983Date of Patent: January 12, 1993Assignee: Centocor, Inc.Inventors: Warren C. Bogard, Jr., Patrick C. Kung
-
Patent number: 5151266Abstract: Methods are disclosed for increasing the solubility of antibodies and their radioisotope, toxin, or drug immunoconjugates and for reducing the non-specific uptake of antibody, either conjugated or unconjugated, into the RES organs such as via Fc receptor-mediated mechanisms. The methods involve incubation of the reactive component with amphipathic molecules, such as an anionic detergent, to achieve the desired result. A preferred anionic detergent in this regard is sodium dodecylsulfate.Type: GrantFiled: December 22, 1988Date of Patent: September 29, 1992Assignee: NeoRx CorporationInventors: A. Charles Morgan, Jr., Gowsala Pavanasasivam
-
Patent number: 5126131Abstract: Undesired immune responses are suppressed by administering a nonimmunogenic material which comprises one or more haptens or epitopes corresponding to the antigen which causes the undesired immune response, the number and spacing of the haptens or epitopes being insufficient to trigger an immune response but sufficient to inhibit it. Also disclosed is an improved vaccine from which low molecular weight suppressive polymer has been removed.Type: GrantFiled: September 21, 1988Date of Patent: June 30, 1992Assignee: The Johns Hopkins UniversityInventors: Howard M. Dintzis, Renee Z. Dintzis
-
Patent number: 5109115Abstract: The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed.Type: GrantFiled: December 5, 1988Date of Patent: April 28, 1992Assignee: The United States of America as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Frank F. Cuttitta, John D. Minna
-
Patent number: 5102658Abstract: A method of preventing controlling or reducing adiposity in which an animal or human being is treated with an effective amount of an antibody to an adipocyte present respectively in said animal or human being.Type: GrantFiled: July 19, 1985Date of Patent: April 7, 1992Assignee: National Research Development CorporationInventor: David J. Flint
-
Patent number: 5096706Abstract: A method of preventing, controlling or reducing adiposity in which an animal or human subject is treated with an immunogen which is a modified or unmodified antigenic substance obtainable from adipose tissue of an individual of the same species as the subject or of a species which is closely related phylogenetically to the species of the subject or which is a modified or unmodified antiidiotypic antibody or fragment thereof to an antibody raised against said antigenic substance whereby an immune response is elicited in the subject effective to prevent, control or reduce adiposity.Type: GrantFiled: March 25, 1986Date of Patent: March 17, 1992Assignee: National Research Development CorporationInventor: David J. Flint
-
Patent number: 5091177Abstract: The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.Type: GrantFiled: May 11, 1990Date of Patent: February 25, 1992Assignee: OncogenInventors: Ingegerd Hellstrom, Joseph P. Brown, Karl E. Hellstrom, Diane Horn, Peter Linsley
-
Patent number: 5089262Abstract: P. aeruginosa E87Ag antigen comprising polysaccharide fraction with molecular weight of about 27,000 which is contained in lipopolysaccharide of P. aeruginosa; anti-P. aeruginosa human or mouse monoclonal antibody which recognizes said E87Ag antigen; and mouse-human or mouse-mouse hybridoma which produces said monoclonal antibody.The monoclonal antibody can be used for making diagnosis and therapy of infections with P. aeruginosa.Type: GrantFiled: June 13, 1990Date of Patent: February 18, 1992Assignee: Teijin LimitedInventors: Shuzo Sawada, Takashi Kawamura, Yasuhiko Masuho, Katsuhiko Tomibe
-
Patent number: 5084559Abstract: The subject invention concerns novel protein A or protein A-like molecules that can be coupled to other materials through a single, defined site on the protein A molecule. Specifically exemplified is Cysteinyl-rProtein A.TM.. The compounds of the invention, for example, Cysteinyl-rProtein A.TM., can be used in processes wherein protein A is used.Type: GrantFiled: March 27, 1987Date of Patent: January 28, 1992Assignee: Repligen CorporationInventor: Albert T. Profy
-
Patent number: 5084558Abstract: A blood substitute and plasma expander comprising a cross-linked, substantially endotoxin-free homoglobin solution and process for preparing same. The process comprises fractionating whole blood, separating out a stromal-free, sterile hemoglobin solution, chromatographically separating endotoxins from said hemoglobin solution and crosslinking the resulting endotoxin-free hemoglobin solution.Type: GrantFiled: November 10, 1987Date of Patent: January 28, 1992Assignee: Biopure CorporationInventors: Carl W. Rausch, Mario Feola
-
Patent number: 5081226Abstract: This invention relates to the identification of short peptide segments of AIDS virus proteins which elicit T cellular immunity, and to a method of inducing cellular immunity to native proteins of the AIDS virus by immunization with short synthetic peptides. Five potential peptides have been identified by searching for regions which can fold as a maximally amphipathic helix. These may be useful to include in either a synthetic peptide- or recombinant fragment- based vaccine.Type: GrantFiled: February 28, 1990Date of Patent: January 14, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jay A. Berzofsky, Charles DeLisi, Hanah Margalit, James L. Cornette, Kemp B. Cease, Cecilia S. Ouyang
-
Patent number: 5078996Abstract: Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be treated by direct administration of therapeutically effective quantities of activated granulocyte-macrophage colony stimulating factor. Homogeneous granulocyte-macrophage colony stimulating factor for use in activating macrophages and monocyte precursors is prepared by recombinant DNA techniques. The gene coding for granylocyte-macrophage colony stimulating factor is isolated and then recombinant protein product expressed in an appropriate expression system. The granulocyte-macrophage colony stimulating factor recovered from the expression system is purified to homogeneity by reverse phase high-performance liquid chromatography.Type: GrantFiled: July 31, 1986Date of Patent: January 7, 1992Assignee: Immunex CorporationInventors: Paul J. Conlon, III, Kenneth H. Grabstein
-
Patent number: 5057598Abstract: Novel monoclonal antibodies are disclosed, the production of which is specified by particular genes contained, conveniently, in biologically pure cultures of self-reproducing carrier cells, such as, but not limited to, ATCC HB 8297 and ATCC HB 8298, such antibodies being reactive with at least part of endotoxin core of Gram-negative bacteria. Processes of prepaU.S. GOVERNMENT RIGHTSThe invention described herein may be manufactured, used and licensed by or for the U.S. Government for governmental purposes only without the payment to the inventors of any royalties thereon.Type: GrantFiled: February 1, 1989Date of Patent: October 15, 1991Assignee: Centocor, Inc.Inventors: Matthew Pollack, Kenneth W. Hunter
-
Patent number: 5053492Abstract: Monoclonal antibodies to Mojave toxin and use for isolation of cross-reacting proteins in Crotalus venoms are disclosed. Hybridomas secreting monoclonal antibodies against Mojave toxin were established. The antibodies were used for identifying cross-reacting proteins in individual C. s. scutulatus and other Crotalus venoms and to isolate Mojave toxin. The antibodies recognized five bands with a pI range from 5.1 to 6.1 in immunoblots of electrofocused crude venom and Mojave toxin purified by immunoaffinity chromatography. The specificity of the antibodies was for the basic subunit of the toxin which resolved into four bands of pI between 9.3 and 9.6. Individual C. s. scutulatus venoms of snakes from Texas and southern Arizona had multiple bands with pI's ranging from 4.9 to 6.3. Cross-reacting proteins were also recognized by antibodies in the electrophoresed venoms of C. basiliscus, C. d. durissus, C. d. terrificus, C. h. horridus, and C. v.Type: GrantFiled: August 7, 1986Date of Patent: October 1, 1991Assignee: Board of Regents, The University of Texas SystemInventors: Eppie D. Rael, Richard J. Salo
-
Patent number: 5053224Abstract: A method of inducing an immunological response to solid tumors is provided wherein anti-idiotype antibodies presenting an internal image of a tumor or antigen are administered to a patient. Monoclonal anti-idiotype antibodies and immortal B lymphocytes that produce them are also provided.Type: GrantFiled: August 26, 1987Date of Patent: October 1, 1991Inventors: Hilary Koprowski, Dorothee Herlyn, Elaine C. DeFreitas
-
Patent number: 5043429Abstract: Peptides which inhibit the binding of von Willebrand Factor to Factor VIII. Monoclonal antibodies capable of specifically binding to the region of von Willebrand Factor containing the Factor VIII binding domain. Improved methods of preparing Factor VIII.Type: GrantFiled: May 1, 1987Date of Patent: August 27, 1991Assignee: Scripps Clinic and Research FoundationInventors: Theodore S. Zimmerman, Paul A. Foster, Carol A. Fulcher
-
Patent number: 5039794Abstract: A novel cell scattering factor, i.e., tumor egress factor (hereinafter "egressin") isolated from a clone derived from a human metastatic melanoma (M3827) which possesses a loose colony morphology and from a human monocytic cell line (U937) and processes for producing the same. Egressin is useful for the production of immunological reagents for the detection and treatment of metastatic lesions, for aiding in the transport of drugs across the blood-brain barrier, and for aiding in the control of the inflammatory response.Type: GrantFiled: September 15, 1987Date of Patent: August 13, 1991Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Marjorie L. Wier, Joseph E. De Larco
-
Patent number: 5032398Abstract: A modified pertussis toxin suitable as a pertussis vaccine having an essentially unmodified B-oligomer and a catalytic subunit which is inactivated by treatment with polyphosphate compounds, sulfhydryl reductants and mild detergents followed by modification of the activated --SH groups to inhibit ADP-ribosylating activity.Type: GrantFiled: August 1, 1986Date of Patent: July 16, 1991Inventor: Harvey R. Kaslow
-
Patent number: 5030717Abstract: An analog-ligand having a conformation that substantially corresponds to the conformation of a hydrolytic transition state of an amide or ester reactant ligand is used to produce receptor molecules of predetermined specificity. The receptor molecules include an antibody combining site that binds to a reactant ligand and thereby stabilizes the tetrahedral carbon atom of the amide or ester hydrolysis transition state of that reactant ligand to catalytically hydrolyze the reactant ligand at a predetermined site.Type: GrantFiled: August 18, 1987Date of Patent: July 9, 1991Assignee: Scripps Clinic and Research FoundationInventors: Alfonso Tramontano, Kim D. Janda, Richard A. Lerner
-
Patent number: RE33897Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R.sup.1 -Gly-R.sup.2 -Gly-, wherein R.sup.1 and R.sup.2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R.sup.1 and R.sup.2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.Type: GrantFiled: March 29, 1989Date of Patent: April 21, 1992Assignee: Scripps Clinic and Research FoundationInventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard A. Houghton